News Overview News Stock Info Analyst Coverage Stock Quote Stock Chart Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Compositon Resources Investor Email Alerts Investor Contacts Presentations Overview News Stock Info Analyst Coverage Stock Quote Stock Chart Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Compositon Resources Investor Email Alerts Investor Contacts Presentations Select Year : 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 Select Category : All Regulatory Non Regulatory Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer Apr 21, 2026 Read more Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress Mar 31, 2026 Read more Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization Mar 06, 2026 Read more Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need Feb 18, 2026 Read more Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment Feb 03, 2026 Read more Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders Dec 31, 2025 Read more Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates Nov 14, 2025 Read more Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months Sep 22, 2025 Read more Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 Sep 17, 2025 Read more Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer Aug 26, 2025 Read more Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships Aug 15, 2025 Read more Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization Jul 15, 2025 Read more Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer Jul 07, 2025 Read more Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic Jun 30, 2025 Read more Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer Jun 27, 2025 Read more Allarity Therapeutics Announces Changes to Board of Directors Jun 11, 2025 Read more Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action Jun 04, 2025 Read more Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer Jun 02, 2025 Read more Allarity Therapeutics Announces Participation in Pharma Partnering Summit US May 12, 2025 Read more Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment May 09, 2025 Read more Quick Links SEC Filings IR Contact [email protected] Investor Email Alerts
